Reviva Pharmaceuticals Holdings Inc. (RVPHW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10080 N WOLFE ROAD CUPERTINO, CA 95014 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 2/29/2020 | 2/28/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 23,367,456 | 18,519,856 | 29,687,944 | 8,760,462 | 69,276 | 313,049 | |||
| Cash and cash equivalent | 23,367,456 | 18,519,856 | 29,687,944 | 8,760,462 | 69,276 | 313,049 | |||
| Other undisclosed current assets | 69,584 | 91,130 | |||||||
| Total current assets: | 23,367,456 | 18,519,856 | 29,687,944 | 8,760,462 | 138,860 | 404,179 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | (41,708) | ||||||||
| Restricted cash and investments | 60,882,949 | 65,241,920 | |||||||
| Other undisclosed noncurrent assets | |||||||||
| Total noncurrent assets: | (41,708) | 60,882,949 | 65,241,920 | ||||||
| Other undisclosed assets | 332,932 | 403,819 | 1,716,057 | 43,524 | |||||
| TOTAL ASSETS: | 23,700,388 | 18,923,675 | 31,404,001 | 8,762,278 | 61,021,809 | 65,646,099 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,208,205 | 3,520,271 | 509,583 | 1,008,046 | 299,653 | 23,050 | |||
| Accounts payable | 3,849,108 | 3,520,271 | 509,583 | 1,008,046 | 299,653 | 23,050 | |||
| Accrued liabilities | 1,359,097 | ||||||||
| Debt | |||||||||
| Derivative instruments and hedges, liabilities | 1,963,785 | ||||||||
| Other undisclosed current liabilities | 11,966,812 | 2,519,569 | 1,835,228 | ||||||
| Total current liabilities: | 17,175,017 | 6,039,840 | 2,344,811 | 2,971,831 | 299,653 | 23,050 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 806,655 | 567,439 | 372,730 | 750,000 | |||||
| Due to related parties | ✕ | ✕ | 750,000 | ||||||
| Derivative instruments and hedges, liabilities | 806,655 | 567,439 | 372,730 | ||||||
| Other undisclosed noncurrent liabilities | 2,213,750 | 2,213,750 | |||||||
| Total noncurrent liabilities: | 806,655 | 567,439 | 372,730 | 2,963,750 | 2,213,750 | ||||
| Other undisclosed liabilities | 324,697 | ||||||||
| Total liabilities: | 17,981,672 | 6,607,279 | 2,717,541 | 3,296,528 | 3,263,403 | 2,236,800 | |||
| Temporary equity, including noncontrolling interest | 52,758,399 | 58,409,291 | |||||||
| Equity | |||||||||
| Equity, attributable to parent | 5,718,716 | 12,316,396 | 28,686,460 | 5,465,750 | 5,000,007 | 5,000,008 | |||
| Common stock | 2,792 | 2,045 | 1,443 | 923 | 3,807,973 | 4,425,877 | |||
| Additional paid in capital | 140,070,172 | 103,485,612 | 95,516,986 | 63,774,920 | |||||
| Retained earnings (accumulated deficit) | (134,354,248) | (91,171,261) | (66,831,969) | (58,310,093) | 1,192,034 | 574,131 | |||
| Total equity: | 5,718,716 | 12,316,396 | 28,686,460 | 5,465,750 | 5,000,007 | 5,000,008 | |||
| TOTAL LIABILITIES AND EQUITY: | 23,700,388 | 18,923,675 | 31,404,001 | 8,762,278 | 61,021,809 | 65,646,099 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 2/29/2020 | 2/28/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (39,503,636) | (24,306,608) | (106,713) | (2,434,651) | (724,740) | (152,789) | ||
| Operating loss: | (39,503,636) | (24,306,608) | (106,713) | (2,434,651) | (724,740) | (152,789) | ||
| Nonoperating income (expense) | 259,748 | (11,907) | (1,347,937) | 1,323,935 | 729,499 | |||
| Investment income, nonoperating | (239,216) | (194,709) | 105,183 | 1,323,935 | 729,499 | |||
| Interest and debt expense | (1,453,120) | |||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (39,243,888) | (24,318,515) | (106,713) | (5,235,708) | 599,195 | 576,710 | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 1,453,120 | |||||||
| Income (loss) from continuing operations before income taxes: | (39,243,888) | (24,318,515) | (106,713) | (3,782,588) | 599,195 | 576,710 | ||
| Income tax expense | (16,949) | (20,777) | (8,281) | (800) | ||||
| Income (loss) from continuing operations: | (39,260,837) | (24,339,292) | (114,994) | (3,783,388) | 599,195 | 576,710 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (114,994) | (3,783,388) | 599,195 | 576,710 | |
| Other undisclosed net income | 18,708 | |||||||
| Net income (loss): | (39,260,837) | (24,339,292) | (114,994) | (3,783,388) | 617,903 | 576,710 | ||
| Other undisclosed net loss attributable to parent | (8,406,882) | (2,579) | ||||||
| Net income (loss) attributable to parent: | (39,260,837) | (24,339,292) | (8,521,876) | (3,783,388) | 617,903 | 574,131 | ||
| Preferred stock dividends and other adjustments | (1,163,534) | (650,811) | ||||||
| Net loss available to common stockholders, diluted: | (39,260,837) | (24,339,292) | (8,521,876) | (3,783,388) | (545,631) | (76,680) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 2/29/2020 | 2/28/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (39,260,837) | (24,339,292) | (114,994) | (3,783,388) | 617,903 | 576,710 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (39,260,837) | (24,339,292) | (114,994) | (3,783,388) | 617,903 | 576,710 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.